# Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer

> **NCT00574275** · PHASE3 · TERMINATED · sponsor: **Sanofi** · enrollment: 546 (actual)

## Conditions studied

- Pancreatic Neoplasm

## Interventions

- **DRUG:** Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
- **DRUG:** Placebo
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00574275
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-12
- **Primary completion:** 2009-10
- **Final completion:** 2010-11
- **Target enrollment:** 546 (ACTUAL)
- **Why stopped:** Data Monitoring Committee concluded after a planned interim analysis that aflibercept added to gemcitabine would be unable to demonstrate improved survival
- **Last updated:** 2016-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00574275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00574275, "Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00574275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*